Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology.

Our lead product, Grafalon®, has been used for over 30 years to treat patients and is available in over 50 countries world wide. It has approval for use in immunosuppressive therapies for prevention of graft- versus- host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation and in treatment of aplastic anemia.

There are differences in approved indications between countries so please refer to local country information for details.